Edesa Biotech (NASDAQ:EDSA)’s stock price traded up 11.6% during mid-day trading on Wednesday . The company traded as high as $6.28 and last traded at $6.15, 117,046 shares were traded during trading. A decline of 45% from the average session volume of 214,274 shares. The stock had previously closed at $5.51.
The stock has a market capitalization of $41.33 million, a PE ratio of -0.67 and a beta of -0.53.
Edesa Biotech (NASDAQ:EDSA) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter. Edesa Biotech had a negative return on equity of 108.60% and a negative net margin of 2,088.28%.
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. The company was founded in 2015 and is headquartered in Markham, Canada.
Further Reading: What do I need to know about analyst ratings?
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.